LongeVC

LongeVC is a venture capital firm dedicated to investing in early-stage biotechnology and longevity-focused companies. The firm's mission is to support visionary founders in bringing breakthrough biotech solutions to market that can significantly impact human healthspan and transform healthcare. LongeVC focuses on pre-clinical and clinical stage drug development companies exploring the molecular and cellular mechanisms of aging, as well as those developing new solutions for personalized medicine, advanced diagnostics, and foundational platform technologies. Their investment strategy encompasses therapeutics, diagnostics & prevention, and longevity infrastructure.

Founded in 2020 by Garri Zmudze, Ilya Suharenko, and Sergey Jakimov, LongeVC was established with the goal of advancing the longevity industry through strategic investments in innovative biotech solutions. The firm aims to extend healthy human lifespan by backing science-driven ventures with strong translational potential. LongeVC is known for its rigorous scientific due diligence and its commitment to fostering a dynamic ecosystem of innovators, connecting founders with a global network of thought leaders.

LongeVC manages a diverse portfolio of companies, typically engaging with startups at the pre-seed, seed, seed-plus, and Series A funding stages. Notable investments include SiPhox Health, which offers at-home health testing; Red Queen Bio, an AI biosecurity company; Valink Therapeutics, developing novel cancer therapeutics; Trogenix, focused on precision cancer treatments; and Insilico Medicine, which applies generative AI for drug discovery. Other portfolio companies like Rubedo Life Sciences, CatenaBio, and Constructive Bio are also at the forefront of developing innovative therapies and biotechnologies.

The firm is led by an experienced team, including Managing Partners Garri Zmudze, Ilya Suharenko, and Sergey Jakimov, alongside a robust investment and operations team, venture partners, and an extensive advisory board. The team's expertise spans venture capital, biotechnology, molecular and cellular biology, bioengineering, and computer science, enabling LongeVC to provide not only capital but also strategic business development support and operational guidance to its portfolio companies.